Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

DelveInsight's "TRYVIO/JERAYGO Market Size, Forecast, and Market Insight Report" highlights the details around TRYVIO/JERAYGO ...

TRYVIO (aprocitentan) in the US and JERAYGO in Europe present significant market potential as novel therapies for patients with hypertension inadequately controlled by existing treatments. TRYVIO ...

In a transformative review, small noncoding RNAs (sncRNAs) have emerged as pivotal regulators in the complex landscape of cardiovascular diseases.

A new systematic review identifies 17 modifiable risk factors shared by stroke, dementia, and late-life depression — offering ...

TNF Pharmaceuticals, Inc. ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, and Renova Health ...

My 15-year-old cat looms over me where I lie in bed, pretending I don’t see her. “Meow,” she says plaintively. I gently shrug ...

and pulmonary hypertension may be particularly relevant to the pathophysiology heart failure in patients with preserved ejection fraction, there is compelling rationale for extending the ...

Chronic cluster headache is undoubtedly one of the toughest clinical challenges of headache medicine. The amount of pain and distress experienced by people with this condition sometimes justifies ...

A compelling naturopathic case study by Dr. Eric Dorninger reveals how endotoxin exposure from kitty litter led to CIRS and ...